References
- Provan D, Bartlett-Pandite L, Zwicky C, . Eradication of polymerase chain reaction-detectable chronic lymphocytic leukemia cells is associated with improved outcome after bone marrow transplantation. Blood 1996;88:2228–2235.
- Boettcher M, Ritgen M, Pott C, . Comparative analysis of minimal residual disease detection using four-color flow cytometry, consensus IgH-PCR, and quantitative IgH PCR in CLL after allogeneic and autologous stem cell transplantation. Leukemia 2004;18: 1637–1645.
- Moreno C, Villamor N, Colomer D, . Clinical significance of minimal residual disease, as assessed by different techniques, after stem cell transplantation for chronic lymphocytic leukemia. Blood 2006;107:4563–4569.
- Esteve J, Villamor N, Colomer D, . Stem cell transplantation for chronic lymphocytic leukemia: different outcome after autologous and allogeneic transplantation and correlation with minimal residual disease status. Leukemia 2001;15:445–451.
- Ritgen M, Stilgenbauer S, Von Neuhoff N, . Graft- versus-leukemia activity may overcome therapeutic resistance of chronic lymphocytic leukemia with unmutated immunoglobulin variable heavy-chain gene status: implications of minimal residual disease measurement with quantitative PCR. Blood 2004;104: 2600–2602.
- Caballero D, Garcia JA, Martino R, . Allogeneic transplant with reduced intensity conditioning regimens may overcome the poor prognosis of B-cell chronic lymphocytic leukemia with unmutated immunoglobulin variable heavy-chain gene and chromosomal abnormalities (11q- and 17p-). Clin Cancer Res 2005;11:7757–7763.
- Dreger P, D¨hner H, Ritgen M, . Allogeneic stem cell transplantation provides durable disease control in poor risk chronic lymphocytic leukemia: long-term clinical and MRD results of the GCLLSG CLL3X trial. Blood 2010;116:2438–2447.
- Farina L, Carniti C, Dodero A, . Qualitative and quantitative polymerase chain reaction monitoring of minimal residual disease in relapsed chronic lymphocytic leukemia: early assessment can predict long-term outcome after reduced intensity allogeneic transplantation. Haematologica 2009;94:654–662.
- Rawstron AC, de Tute R, Jack AS, Hillmen P. Flow-cytometric protein expression profiling as a systematic approach for developing disease-specific assays: identification of a chronic lymphocytic leukaemia-specific assay for use in rituximab containing regimes. Leukemia 2006;20:2102–2110.
- Rawstron A, Villamor N, Ritgen M, . International standardized approach for flow-cytometric residual disease monitoring in chronic lymphocytic leukemia. Leukemia 2007;21:956–964.